Gastrointestinal Cancer

>

Latest News

The pre-specified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.
Tovecimig Yields Significant Responses in Advanced Biliary Tract Cancer

April 4th 2025

The pre-specified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers
A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

April 2nd 2025

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.
PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases

March 31st 2025

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer
Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

March 31st 2025

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.
Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

March 31st 2025

Latest CME Events & Activities

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

View More

<1
...
5152535455